| Literature DB >> 31214866 |
Peter Stegman1, Bridget Stirling2, Brad Corner3, Melissa Schnure4, Denis Mali3, Ella Shihepo5, Katharine Kripke6, Emmanuel Njeuhmeli7.
Abstract
Voluntary Medical Male circumcision (VMMC) has been part of prevention in Namibia since 2009. Yet, as of 2013, VMMC coverage among 15- to 24-year-olds was estimated at less than 22%. Program data suggests uptake of VMMC below age 15 is lower than expected, given the age distribution of the eligible population. Nearly 85% of VMMCs were for males between ages 15 and 29, while boys 10-14 years were referred outside the program. This analysis uses the Decision Makers Program Planning Tool to understand the impact of age prioritization on circumcision in Namibia. Results indicate that circumcising males aged 20-29 reduced HIV incidence most rapidly, while focusing on ages 15-24 was more cost effective and produced greater magnitude of impact. Providing services to those under 15 could increase VMMC volume 67% while introducing Early Infant Medical Circumcision could expand coverage. This exercise supported a review of VMMC strategies and implementation, with Namibia increasing coverage among 10- to 14-year-olds nearly 20 times from 2016 to 2017.Entities:
Keywords: HIV prevention; HIV/AIDS; Namibia; Sub-Saharan Africa; VMMC
Mesh:
Year: 2019 PMID: 31214866 PMCID: PMC6773676 DOI: 10.1007/s10461-019-02556-y
Source DB: PubMed Journal: AIDS Behav ISSN: 1090-7165
Modelling scenarios exploring potential increases in circumcision coverage by introducing EIMC into the national VMMC program
| National VMMC program scale up strategies | ||
|---|---|---|
| Scenario 1 | Scenario 2 | Scenario 3 |
| Base strategy | Intensive EMIC introduction | Mixed scale up strategy |
| Targeting 80% VMMC coverage for 10- to 34-year-olds only for national program scale up over 5 years and maintained at 80% thereafter | Targeting 80% coverage of 10- to 34-year-olds as in the base strategy, and including a target of 80% EIMC coverage over the same time period | Targeting 80% coverage of 10- to 34-year-olds as in the base strategy, and including a target of only 40% EIMC coverage over the same time period |
Scale up scenarios examining the potential impact of the PEPFAR age prioritization policy
| PEPFAR age prioritization policy scale up strategies | ||
|---|---|---|
| Scenario 1 | Scenario 2 | Scenario 3 |
| Aggressive scale up 15–29 years | Sustained coverage 15–29 years | Very aggressive scale up 15–29 years |
| VMMC coverage of 15- to 29-year-olds increased by 50% above 2016 levels; VMMC coverage to 10- to 14-year-olds unchanged from 2016 levels | VMMC coverage of 15- to 29-year-olds unchanged from 2016 levels; no VMMC services provided to 10- to 14-year-olds | Very coverage 15- to 29-year-olds increased by 100% above 2016 levels; VMMC coverage of 10- to 14-year-olds increased by 100% above 2016 levels |
Fig. 1Relative reduction in HIV incidence for specific age groups compared with incidence in a population with no VMMC, 2015–2051
Fig. 2Number of circumcisions required to avert one HIV infection by age group in Namibia, over a 15-years period from 2016 to 2030
Fig. 3The cost per infection averted of different age grouping strategies in Namibia from 2016 to 2030
Fig. 4Three VMMC scale-up scenarios: a the number of circumcisions needing to be performed, by age group to achieve a scale up target of 80% coverage among 10- to 34-year-olds only; b the number of circumcisions needing to be performed, by age group to achieve a scale up target of 80% coverage among 10- to 34-year-olds + scale-up of EIMC to 80% coverage; c the number of circumcisions needing to be performed, by age group to achieve a scale up target of 80% coverage among 10- to 34-year-olds + scale-up of EIMC to 40% coverage
Summary of three scenarios presenting VMMC coverage addressing PEPFAR age prioritization policy over a five-year period
| PEPFAR policy standard | 15–29 coverage start 2016 (%) | 15–29 coverage start 2022 (%) | Increase in 15–29 coverage (%) |
|---|---|---|---|
| Scenario 1 | |||
| Aggressive VMMC provision for 15–29 and constant VMMC provision for 10–14 | 23 | 45 | 22 |
| Scenario 2 | |||
| Constant VMMC provision for 15–29 and no VMMC provision for 10–14 | 23 | 39 | 16 |
| Scenario 3 | |||
| Very aggressive VMMC provision for 15–29 and aggressive VMMC provision for 10–14 | 23 | 50 | 27 |
The impact of adding EIMC to the national VMMC program from 2016 to 2050
| Impact of adding EIMC | |||
|---|---|---|---|
| 10–34 years | 10–34 + EIMC | % Increase | |
| Infection averted | 26,000 | 28,000 | 7.6 |
| Number of MCs | 0.9 million | 1.2 million | 33.0 |
| % Infection averted | 34% | 36% | 2.0 |
| VMMC per infection averted | 39 | 49 | 25.6 |
The cost and cost-effectiveness of introducing EIMC to the scale up of the national VMMC program over the period 2016–2050
| Cost and cost-effectiveness of adding EIMC | |||
|---|---|---|---|
| 10–34 years | 10–34 + EIMC | % Difference | |
| EIMC cost at 100% of adult VMMC cost | |||
| Total cost | $122 million | $156 million | 25 |
| Cost per infection averted | $5163.25 | $6527.22 | 23 |
| EIMC cost at 50% of adult VMMC cost | |||
| Total cost | $122 million | $106 million | − 14 |
| Cost per infection averted | $5163.25 | $4606.79 | − 11 |
| EIMC cost at 25% of adult VMMC cost | |||
| Total cost | $122 million | $81 million | − 40 |
| Cost per infection averted | $5163.25 | $3646.57 | − 34 |
Fig. 5VMMCs performed by year in the age groups 10 to 34 years